Rituxan and MabThera are trade names for the medication Rituximab, a biologic therapy designed by Roche. It is primarily used to treat conditions like non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, among other autoimmune disorders. The revolutionary monoclonal antibody acts by targeting specific cells, thereby enhancing your body’s natural defense against these diseases. Operating in the English language, Roche continues to provide pivotal information on dosages, usage, and side effects associated with the administration of Rituximab.